Modality
Fusion Protein
MOA
BTKi
Target
PD-L1
Pathway
Complement
IPFGIST
Development Pipeline
Preclinical
~Nov 2020
→ ~Feb 2022
Phase 1
~May 2022
→ ~Aug 2023
Phase 2
Nov 2023
→ Jul 2027
Phase 2Current
NCT07809906
2,006 pts·IPF
2023-11→2027-07·Recruiting
2,006 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-011.3y awayPh3 Readout· IPF
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-07-01 · 1.3y away
IPF
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07809906 | Phase 2/3 | IPF | Recruiting | 2006 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| BAY-3684 | Bayer | Approved | PD-L1 |